Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25045216 | 1.00 | FDPS (0.32) | FDPSSMN1; SMN2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL480913 | 0.97 | — | — | |
| SCHEMBL6671282 | 0.97 | — | — | |
| SCHEMBL20907944 | 0.92 | — | — | |
| Oxalic Acid SCHEMBL9536603 | 0.87 | KDM4E (0.38) | FDPSSMN1; SMN2 | |
| SCHEMBL1045044 | 0.85 | — | — | |
| SCHEMBL26578008 | 0.78 | CHRNA7 (0.34) | CYP2D6KCNH2 | |
| SCHEMBL28537860 | 0.78 | TDP1 (0.37) | FDPSSMN1; SMN2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL26082686 | 0.76 | FDPS (0.31) | FDPS | |
| SCHEMBL3742323 | 0.76 | MC4R (0.39) | CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157912-A1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | Covestro Deutschland AG (DE) | 2023-04-05 | — | — | EP | disclosed |
| EP-3997183-A1 | METHOD FOR PRODUCING ISOCYANURATES FROM URETDIONES | Covestro Intellectual Property GmbH & Co. KG (DE) | 2022-05-18 | — | — | EP | disclosed |
| EP-3997141-A1 | PROCESS OF PREPARING ALLOPHANATE- AND/OR THIOALLOPHANATE GROUP-CONTAINING COMPOUNDS | Covestro Intellectual Property GmbH & Co. KG (DE) | 2022-05-18 | — | — | EP | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2021239678-A1 | COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES | COVESTRO DEUTSCHLAND AG (DE) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021004978-A1 | METHOD FOR PRODUCING ISOCYANURATES FROM URETDIONES | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2021-01-14 | — | — | WO | disclosed |
| WO-2021004980-A1 | PROCESS OF PREPARING ALLOPHANATE- AND/OR THIOALLOPHANATE GROUP-CONTAINING COMPOUNDS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2021-01-14 | — | — | WO | disclosed |
| WO-2020156937-A1 | ISOCYANATE-TERMINATED PREPOYLMERS FOR TEXTILE COATINGS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020064631-A1 | LOW-SOLVENT COATING SYSTEMS FOR TEXTILES | COVESTRO DEUTSCHLAND AG (DE) | 2020-04-02 | — | — | WO | disclosed |
| EP-3441392-A1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Intellikine, LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-1795527-A1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-1315768-A1 | COMPOSITE ELEMENTS CONTAINING POLYISOCYANATE POLYADDITION PRODUCTS | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-6534521-B2 | Useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
| WO-2002016460-A1 | COMPOSITE ELEMENTS CONTAINING POLYISOCYANATE POLYADDITION PRODUCTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-28 | — | — | WO | disclosed |
| US-6348487-B1 | ANTIINFLAMMATORY AGENTS, ATHEROSCLEROSIS, RESTINOSIS AND IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6184235-B1 | MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) ANTAGONIST FOR TREATMENT OF INFLAMMATORY DISEASES, ATHEROSCLEROSIS, RESTENOSIS, AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION IN MAMMALS | WARNER-LAMBERT COMPANY | 2001-02-06 | — | — | US | disclosed |
| EP-0927167-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998006703-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0151826-B1 | 4-[(Bicyclic heterocyclyl)-methyl and -hetero]-piperidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | FDPS 4589/4885SMN1; SMN2 3655/4885CYP1A2 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.